CME GROUP INC (CME) Fundamental Analysis & Valuation

NASDAQ:CME • US12572Q1058

320 USD
-5.13 (-1.58%)
At close: Mar 4, 2026
319 USD
-1 (-0.31%)
After Hours: 3/4/2026, 4:30:00 PM

This CME fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to CME. CME was compared to 238 industry peers in the Capital Markets industry. CME has an average financial health and profitability rating. CME is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

6

1. CME Profitability Analysis

1.1 Basic Checks

  • In the past year CME was profitable.
  • CME had a positive operating cash flow in the past year.
  • Each year in the past 5 years CME has been profitable.
  • Of the past 5 years CME 4 years had a positive operating cash flow.
CME Yearly Net Income VS EBIT VS OCF VS FCFCME Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B

1.2 Ratios

  • CME has a Return On Assets of 1.99%. This is comparable to the rest of the industry: CME outperforms 42.86% of its industry peers.
  • CME has a Return On Equity of 13.18%. This is in the better half of the industry: CME outperforms 72.27% of its industry peers.
  • CME has a Return On Invested Capital of 18.56%. This is amongst the best in the industry. CME outperforms 94.12% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for CME is significantly above the industry average of 7.27%.
Industry RankSector Rank
ROA 1.99%
ROE 13.18%
ROIC 18.56%
ROA(3y)2.34%
ROA(5y)1.97%
ROE(3y)13.02%
ROE(5y)11.7%
ROIC(3y)18.73%
ROIC(5y)14.69%
CME Yearly ROA, ROE, ROICCME Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5 10 15 20

1.3 Margins

  • CME has a Profit Margin of 32.91%. This is in the better half of the industry: CME outperforms 76.89% of its industry peers.
  • In the last couple of years the Profit Margin of CME has declined.
  • With an excellent Operating Margin value of 80.16%, CME belongs to the best of the industry, outperforming 98.74% of the companies in the same industry.
  • CME's Operating Margin has improved in the last couple of years.
Industry RankSector Rank
OM 80.16%
PM (TTM) 32.91%
GM N/A
OM growth 3Y4.02%
OM growth 5Y7.87%
PM growth 3Y-3.77%
PM growth 5Y-4.62%
GM growth 3YN/A
GM growth 5YN/A
CME Yearly Profit, Operating, Gross MarginsCME Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60 80 100

5

2. CME Health Analysis

2.1 Basic Checks

  • CME has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for CME has been increased compared to 5 years ago.
  • The debt/assets ratio for CME has been reduced compared to a year ago.
CME Yearly Shares OutstandingCME Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M
CME Yearly Total Debt VS Total AssetsCME Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50B 100B 150B

2.2 Solvency

  • CME has an Altman-Z score of 0.73. This is a bad value and indicates that CME is not financially healthy and even has some risk of bankruptcy.
  • CME has a Altman-Z score (0.73) which is in line with its industry peers.
  • CME has a debt to FCF ratio of 0.85. This is a very positive value and a sign of high solvency as it would only need 0.85 years to pay back of all of its debts.
  • With an excellent Debt to FCF ratio value of 0.85, CME belongs to the best of the industry, outperforming 89.08% of the companies in the same industry.
  • A Debt/Equity ratio of 0.12 indicates that CME is not too dependend on debt financing.
  • CME's Debt to Equity ratio of 0.12 is fine compared to the rest of the industry. CME outperforms 77.73% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF 0.85
Altman-Z 0.73
ROIC/WACCN/A
WACCN/A
CME Yearly LT Debt VS Equity VS FCFCME Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B 20B 25B

2.3 Liquidity

  • A Current Ratio of 1.02 indicates that CME should not have too much problems paying its short term obligations.
  • CME has a Current ratio of 1.02. This is comparable to the rest of the industry: CME outperforms 46.22% of its industry peers.
  • CME has a Quick Ratio of 1.02. This is a normal value and indicates that CME is financially healthy and should not expect problems in meeting its short term obligations.
  • With a Quick ratio value of 1.02, CME perfoms like the industry average, outperforming 46.64% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.02
Quick Ratio 1.02
CME Yearly Current Assets VS Current LiabilitesCME Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50B 100B 150B

5

3. CME Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 9.26% over the past year.
  • Measured over the past years, CME shows a quite strong growth in Earnings Per Share. The EPS has been growing by 10.74% on average per year.
  • The Revenue has grown by 20.06% in the past year. This is a very strong growth!
  • The Revenue has been growing by 19.33% on average over the past years. This is quite good.
EPS 1Y (TTM)9.26%
EPS 3Y12%
EPS 5Y10.74%
EPS Q2Q%9.92%
Revenue 1Y (TTM)20.06%
Revenue growth 3Y19.31%
Revenue growth 5Y19.33%
Sales Q2Q%8.09%

3.2 Future

  • The Earnings Per Share is expected to grow by 4.89% on average over the next years.
  • The Revenue is expected to grow by 5.26% on average over the next years.
EPS Next Y5.6%
EPS Next 2Y5.94%
EPS Next 3Y6.61%
EPS Next 5Y4.89%
Revenue Next Year6.64%
Revenue Next 2Y6.11%
Revenue Next 3Y6.51%
Revenue Next 5Y5.26%

3.3 Evolution

  • The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
CME Yearly Revenue VS EstimatesCME Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2B 4B 6B 8B 10B
CME Yearly EPS VS EstimatesCME Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 5 10

2

4. CME Valuation Analysis

4.1 Price/Earnings Ratio

  • CME is valuated quite expensively with a Price/Earnings ratio of 28.55.
  • Based on the Price/Earnings ratio, CME is valued a bit more expensive than the industry average as 73.53% of the companies are valued more cheaply.
  • CME is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 26.83, which is the current average of the S&P500 Index.
  • CME is valuated quite expensively with a Price/Forward Earnings ratio of 27.03.
  • 65.13% of the companies in the same industry are cheaper than CME, based on the Price/Forward Earnings ratio.
  • CME's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 24.95.
Industry RankSector Rank
PE 28.55
Fwd PE 27.03
CME Price Earnings VS Forward Price EarningsCME Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, CME is valued cheaply inside the industry as 83.19% of the companies are valued more expensively.
  • CME's Price/Free Cash Flow is on the same level as the industry average.
Industry RankSector Rank
P/FCF 28.26
EV/EBITDA 12.58
CME Per share dataCME EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates CME does not grow enough to justify the current Price/Earnings ratio.
  • CME has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)5.09
PEG (5Y)2.66
EPS Next 2Y5.94%
EPS Next 3Y6.61%

4

5. CME Dividend Analysis

5.1 Amount

  • CME has a Yearly Dividend Yield of 1.60%.
  • Compared to an average industry Dividend Yield of 6.44, CME is paying slightly less dividend.
  • Compared to an average S&P500 Dividend Yield of 1.82, CME has a dividend comparable with the average S&P500 company.
Industry RankSector Rank
Dividend Yield 1.6%

5.2 History

  • On average, the dividend of CME grows each year by 16.00%, which is quite nice.
  • CME has paid a dividend for at least 10 years, which is a reliable track record.
  • CME has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.
Dividend Growth(5Y)16%
Div Incr Years11
Div Non Decr Years11
CME Yearly Dividends per shareCME Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2 4 6 8 10

5.3 Sustainability

  • CME pays out 104.85% of its income as dividend. This is not a sustainable payout ratio.
  • CME's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
DP104.85%
EPS Next 2Y5.94%
EPS Next 3Y6.61%
CME Yearly Income VS Free CF VS DividendCME Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B
CME Dividend Payout.CME Dividend Payout, showing the Payout Ratio.CME Dividend Payout.PayoutRetained Earnings

CME Fundamentals: All Metrics, Ratios and Statistics

CME GROUP INC

NASDAQ:CME (3/4/2026, 4:30:00 PM)

After market: 319 -1 (-0.31%)

320

-5.13 (-1.58%)

Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)02-04
Earnings (Next)04-21
Inst Owners91.62%
Inst Owner Change1.79%
Ins Owners0.24%
Ins Owner Change0%
Market Cap115.39B
Revenue(TTM)12.26B
Net Income(TTM)3.72B
Analysts71
Price Target308.13 (-3.71%)
Short Float %1.5%
Short Ratio2.52
Dividend
Industry RankSector Rank
Dividend Yield 1.6%
Yearly Dividend9.97
Dividend Growth(5Y)16%
DP104.85%
Div Incr Years11
Div Non Decr Years11
Ex-Date03-10
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)0.59%
Min EPS beat(2)0.43%
Max EPS beat(2)0.76%
EPS beat(4)3
Avg EPS beat(4)0.49%
Min EPS beat(4)-1.28%
Max EPS beat(4)2.05%
EPS beat(8)6
Avg EPS beat(8)0.72%
EPS beat(12)10
Avg EPS beat(12)0.95%
EPS beat(16)14
Avg EPS beat(16)1.13%
Revenue beat(2)0
Avg Revenue beat(2)-0.83%
Min Revenue beat(2)-1.11%
Max Revenue beat(2)-0.54%
Revenue beat(4)0
Avg Revenue beat(4)-0.98%
Min Revenue beat(4)-1.72%
Max Revenue beat(4)-0.54%
Revenue beat(8)0
Avg Revenue beat(8)-0.81%
Revenue beat(12)3
Avg Revenue beat(12)7.34%
Revenue beat(16)7
Avg Revenue beat(16)10.88%
PT rev (1m)5.04%
PT rev (3m)5.7%
EPS NQ rev (1m)-0.15%
EPS NQ rev (3m)2.89%
EPS NY rev (1m)0.1%
EPS NY rev (3m)1.02%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)3.54%
Revenue NY rev (1m)1.26%
Revenue NY rev (3m)2.41%
Valuation
Industry RankSector Rank
PE 28.55
Fwd PE 27.03
P/S 10.22
P/FCF 28.26
P/OCF 27.73
P/B 4.09
P/tB N/A
EV/EBITDA 12.58
EPS(TTM)11.21
EY3.5%
EPS(NY)11.84
Fwd EY3.7%
FCF(TTM)11.33
FCFY3.54%
OCF(TTM)11.54
OCFY3.61%
SpS31.32
BVpS78.18
TBVpS-6.01
PEG (NY)5.09
PEG (5Y)2.66
Graham Number140.42
Profitability
Industry RankSector Rank
ROA 1.99%
ROE 13.18%
ROCE 24.11%
ROIC 18.56%
ROICexc 19.93%
ROICexgc 150.6%
OM 80.16%
PM (TTM) 32.91%
GM N/A
FCFM 36.16%
ROA(3y)2.34%
ROA(5y)1.97%
ROE(3y)13.02%
ROE(5y)11.7%
ROIC(3y)18.73%
ROIC(5y)14.69%
ROICexc(3y)20.74%
ROICexc(5y)16.19%
ROICexgc(3y)290.88%
ROICexgc(5y)224.49%
ROCE(3y)24.31%
ROCE(5y)19.07%
ROICexgc growth 3Y16.89%
ROICexgc growth 5Y15.23%
ROICexc growth 3Y24.21%
ROICexc growth 5Y29.59%
OM growth 3Y4.02%
OM growth 5Y7.87%
PM growth 3Y-3.77%
PM growth 5Y-4.62%
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF 0.85
Debt/EBITDA 0.37
Cap/Depr 23.26%
Cap/Sales 0.68%
Interest Coverage 66.76
Cash Conversion 44.34%
Profit Quality 109.88%
Current Ratio 1.02
Quick Ratio 1.02
Altman-Z 0.73
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)9.26%
EPS 3Y12%
EPS 5Y10.74%
EPS Q2Q%9.92%
EPS Next Y5.6%
EPS Next 2Y5.94%
EPS Next 3Y6.61%
EPS Next 5Y4.89%
Revenue 1Y (TTM)20.06%
Revenue growth 3Y19.31%
Revenue growth 5Y19.33%
Sales Q2Q%8.09%
Revenue Next Year6.64%
Revenue Next 2Y6.11%
Revenue Next 3Y6.51%
Revenue Next 5Y5.26%
EBIT growth 1Y12.23%
EBIT growth 3Y24.1%
EBIT growth 5Y28.72%
EBIT Next Year10.74%
EBIT Next 3Y9.04%
EBIT Next 5Y6.41%
FCF growth 1Y12.56%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.95%
OCF growth 3YN/A
OCF growth 5YN/A

CME GROUP INC / CME FAQ

What is the ChartMill fundamental rating of CME GROUP INC (CME) stock?

ChartMill assigns a fundamental rating of 5 / 10 to CME.


What is the valuation status of CME GROUP INC (CME) stock?

ChartMill assigns a valuation rating of 2 / 10 to CME GROUP INC (CME). This can be considered as Overvalued.


Can you provide the profitability details for CME GROUP INC?

CME GROUP INC (CME) has a profitability rating of 6 / 10.


What is the earnings growth outlook for CME GROUP INC?

The Earnings per Share (EPS) of CME GROUP INC (CME) is expected to grow by 5.6% in the next year.


Can you provide the dividend sustainability for CME stock?

The dividend rating of CME GROUP INC (CME) is 4 / 10 and the dividend payout ratio is 104.85%.